Provided by Tiger Fintech (Singapore) Pte. Ltd.

Autolus Therapeutics PLC

1.43
+0.08005.93%
Post-market: 1.490.0600+4.20%18:20 EDT
Volume:1.17M
Turnover:1.67M
Market Cap:380.56M
PE:-1.65
High:1.49
Open:1.34
Low:1.33
Close:1.35
Loading ...

European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week

MT Newswires Live
·
28 Dec 2024

European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading

MT Newswires Live
·
27 Dec 2024

European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading

MT Newswires Live
·
24 Dec 2024

European Equities Traded in the US as American Depositary Receipts Tumble in Friday Trading; Down 4.6% for Week

MT Newswires Live
·
21 Dec 2024

European Equities Traded in the US as American Depositary Rise in Wednesday Trading

MT Newswires Live
·
19 Dec 2024

European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading

MT Newswires Live
·
17 Dec 2024

European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading

MT Newswires Live
·
12 Dec 2024

Autolus Therapeutics presents clinical data updates at ASH meeting

TIPRANKS
·
10 Dec 2024

Autolus Therapeutics Price Target Maintained With a $10.00/Share by Needham

Dow Jones
·
09 Dec 2024

Autolus Therapeutics: Undervalued Potential in ALL Treatment with Obe-cel

TIPRANKS
·
09 Dec 2024

Autolus Therapeutics plc (AUTL): A Bull Case Theory

Insider Monkey
·
06 Dec 2024

Positive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T Therapy

TIPRANKS
·
06 Dec 2024

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading

MT Newswires Live
·
05 Dec 2024

European Equities Traded in the US as American Depositary Decline in Tuesday Trading

MT Newswires Live
·
27 Nov 2024

Stock Track | Autolus Therapeutics Soars 9.7% in Pre-Market on Analyst Upgrade and FDA Approval Prospects

Stock Track
·
18 Nov 2024

Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7

MT Newswires Live
·
18 Nov 2024

Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated

TIPRANKS
·
18 Nov 2024

Redburn Atlantic Upgrades Autolus Therapeutics to Buy From Neutral, Price Target is $13

MT Newswires Live
·
15 Nov 2024

Stock Track | Autolus Therapeutics Soars 5.65% Pre-Market on Groundbreaking CAR T-Cell Therapy Approval

Stock Track
·
15 Nov 2024

Stock Track | Autolus Therapeutics Surges 9.30% on Positive Developments in CAR T-Cell Therapy

Stock Track
·
15 Nov 2024